[Ip-health] MSF secures generic hepatitis C treatment at $120 compared to $147, 000 launch price tag

Danny Edwards dedwards at accesstomedicinefoundation.org
Thu Nov 2 09:28:17 PDT 2017

Is there more information available on who the generic manufacturers
producing the supply for MSF are, and the terms of the licensing agreement
(if it’s under a VL w/ Gilead and BMS)?

On Tue, 31 Oct 2017 at 16:46, Shailly GUPTA <Shailly.GUPTA at geneva.msf.org>

> MSF secures generic hepatitis C treatment at $120 compared to $147,000
> launch price tag
> Dramatic price drops should allow countries to provide treatment for
> millions of people
> Geneva/Sao Paulo, 31 October 2017-On the eve of the World Hepatitis Summit
> in Sao Paulo, the international medical humanitarian organization Médecins
> Sans Frontières (MSF) today announced that it had secured deals for generic
> hepatitis C medicines for as low as US$1.40 per day, or $120 per 12-week
> treatment course for the two key medicines sofosbuvir and daclatasvir.
> In the US, pharmaceutical corporation Gilead launched sofosbuvir at $1,000
> per pill in 2013, and Bristol-Myers Squibb (BMS) launched daclatasvir at
> $750 per pill in 2015, leading to the original price tag of $147,000 for a
> person's 12-week combination treatment course. The corporations have also
> been charging exorbitant prices in many developing countries, paralyzing
> the launch of national treatment programs and causing treatment rationing
> in many countries around the world.
> "What good is a breakthrough medicine that people cannot afford?" asked
> Jessica Burry, Pharmacist for MSF's Access Campaign. "Pharmaceutical
> corporations price hepatitis C medicines far out of reach for people paying
> out of pocket around the world, and also for many governments struggling to
> provide treatment in the public sectors; but the prices for generic
> versions keep coming down. Governments must use every tool in their toolbox
> to fight for access to lower-priced generics so they can scale up treatment
> for the millions of people who need it; they should follow the lead of
> countries like Malaysia and issue compulsory licenses when patents block
> people's access to this life-saving treatment."
> In 2015, MSF started procuring sofosbuvir and daclatasvir from Gilead and
> BMS through their 'access programs' at a price of $1,400 to $1,800 per
> 12-week treatment. Today, MSF pays a fraction of that, at $120, sourced
> from quality-assured generic manufacturers.
> An estimated 71 million people have chronic hepatitis C infection
> worldwide, 72 per cent of whom live in low- and middle-income countries.
> Direct-acting antiviral medicines (DAAs) represent a treatment breakthrough
> for people with hepatitis C, with cure rates of up to 95%, and with far
> fewer side effects than previous treatments. Yet access to DAAs has
> remained limited because pharmaceutical corporations charge unaffordable
> prices, leading many countries to reserve treatment only for people with
> the most advanced stages of the disease. By the end of 2016, three years
> after sofosbuvir was launched, only an estimated 2.1 million people
> globally had been treated with the medicines, leaving 69 million people
> still without access.
> These high prices have also put a major strain on health systems in
> wealthy countries, in particular those enacting universal health care.
> Treatment is being rationed in countries such as Australia, Canada, Italy
> and the US, in addition to developing countries, and is a stark reminder of
> the early days of HIV treatment.
> "Almost two decades ago, MSF and others worked hard to get access to
> generics and bring down prices for HIV medicines," said Mickael Le Paih of
> MSF in Cambodia, where MSF treats people living with hepatitis C. "History
> is repeating itself with hepatitis C-the medicines we need are again too
> expensive, but we are finding ways to make treatment affordable so that our
> patients can be cured."
> ###
> MSF treats people with hepatitis C in 11 countries. Since 2015, MSF has
> provided DAA treatment to nearly 5,000 people with hepatitis C.  Of those
> who have completed treatment to date, the overall cure rate - measured by
> 'sustained viral response' - is 94.9 per cent.
> Reading Material:
> Not Even Close: This issue brief provides information on currently
> available HCV diagnostics and treatments, including pricing and
> registration information from manufacturers of DAAs
> www.msfaccess.org/hep-c-not-even-close<
> http://www.msfaccess.org/hep-c-not-even-close>
> Shailly Gupta
> Press & Communications Officer
> MSF Access Campaign
> Médecins Sans Frontières
> Ph: +41 22 849 9334
> M: +41 79 203 13 02
> Skype: Shailly.17 |Twitter: @shaillytweeting
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org
Sent from Gmail Mobile

More information about the Ip-health mailing list